|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02162 KEYMED BIO-B
Nominal 
43.850 +3.050 (+7.475%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 428,124 | 20.907% | 354,095 | 100,063 | 110,269 | 0 |
| Cost of Sales | (12,200) | -66.918% | (36,878) | (2,585) | (17,200) | -- |
| Gross Profit | 415,924 | 31.117% | 317,217 | 97,478 | 93,069 | -- |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | (3,480,294) | (696,470) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | (37,932) | (280) | |
| Share of Results of Asso. & JCEs | (5,256) | 10.699% | (4,748) | (9,711) | (719) | 0 | |
| Profit / (Loss) before Taxation | (508,647) | 42.803% | (356,188) | (303,597) | (3,892,632) | (818,848) | |
| Taxation | (6,260) | 291.985% | (1,597) | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (334) | -78.753% | (1,572) | (4,518) | 5,323 | 265 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (515,241) | 43.379% | (359,357) | (308,115) | (3,887,309) | (818,583) | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (69,869) | -1.713% | (71,087) | (45,919) | 4,120 | 8,826 |
| Depreciation & Amortisation | 93,228 | 34.799% | 69,161 | 36,123 | 21,019 | 18,992 |
| Directors' Emoluments | -- | -- | 11,143 | 10,208 | 7,728 | 1,171 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -197.000 | 43.796% | -137.000 | -118.000 | -2,417.000 | -1,220.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (1.162) | (1.539) | (1.334) | (1.779) |
| NBV per share ($) | 8.846 | -- | 10.675 | 11.941 | 13.052 | -- |
| Remarks: | Real time quote last updated: 11/04/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -515,241,000 |
| %Change | 43.379% |
| EPS / (LPS) | RMB -1.970 |
| NBV Per Share (¥) | RMB 8.846 |